ScreenerHero

EQ Equillium, Inc.

NAS · US · Healthcare · Biotechnology · equilliumbio.com
1.390USD-2.11%Mkt Cap: 88.14M $P/E: —

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR m…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap88.14M USD
Enterprise Value33.46M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.40M USD
Revenue/Share—
Last Price1.390 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.06
PEG—
EV/EBITDA-1.74
EV/Revenue—
P/S—
P/B1.61
EPS (TTM)-0.14
EPS (Forward)-0.23
52W Range
0.760023% of range3.540
52W High3.540 USD
52W Low0.7600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-78.32%
ROA-70.24%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.75M USD
CapEx (TTM)48.00K USD
FCF Margin—
FCF Yield-16.22%
Net Debt-56.58M USD
Net Debt/EBITDA2.95
Balance Sheet
Debt/Equity0.03
Current Ratio23.40
Quick Ratio23.07
Book Value/Sh0.88 USD
Cash/Share0.90 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.556 USD
Upside (mean)+515.5%
Target Range4.000 USD – 20.00 USD
4.000+515.5% to mean20.00
# Analysts9
Ownership
Shares Out.63.41M
Float36.97M
Insiders16.00%
Institutions65.76%
Short Interest
Short Ratio13.9d
Short % Float10.05%
Short % Out.8.67%
Shares Short5.50M
Short (prev mo.)5.53M
Technical
SMA 502.111 (-34.1%)
SMA 2002.076 (-33.0%)
Beta1.92
S&P 52W Chg16.45%
Avg Vol (30d)612.56K
Avg Vol (10d)991.26K
Technical Indicators
RSI (14)26.6
MACD-0.2270
MACD Signal-0.1942
MACD Hist.-0.0329
BB Upper2.538 USD
BB Middle1.833 USD
BB Lower1.129 USD
BB Width76.83%
ATR (14)0.1539 USD
Vol Ratio (20d)0.45x